Opdivo, Keytruda and other immunological check point inhibitors mainly lift the body's T cells in the "immune suppression" state by blocking the PD-1 / PD-L1 signaling pathway so that T cells are activated to kill tumor cells. The problem is that these drugs are not effective for all cancer patients, and the reasons are not yet fully elucidated. Thus, more research involving recombinant horse proteins should be conducted.

Scientists at Emory University in the United States recently published in Science and said, "To make the immune suppression of T cells activated and a large number of proliferation response, in addition to the need for Opdivo, Keytruda and other immunological check point inhibitors, but also need other 'fuel'. In the mouse experiment, if the use of genetic engineering technology to knock out the CD28 expression gene or the use of antibodies to block the expression of CD28, T cells couldn't respond to PD-1 inhibitors and achieve substantial amplification."

In order to verify the effect of this finding on the human body, the scientists at Emory University contacted the oncologists of the Winship Cancer Institute to analyze tumor tissue samples from NSCLC patients who received PD-1 inhibitor therapy. In these T cells, the proportion of CD28-positive cells was poor, ranging from 20% to 90%, suggesting that only a small fraction of T cells responded to PD-1 and amplified.

The FDA-approved immunoassay inhibitor is only effective for a small number of patients, and many biopharmaceutical companies see the "more effective inhibition of immunological checkpoint signaling pathways" as the highest priority research and development direction, and therefore they carried out a variety of immunotherapy drugs and other drugs combined with the study, such as Opdivo and Johnson & Johnson JNJ-64041757 combined treatment of NSCLC, Keytruda and Anjin the oncolytic virus Imlygic combined treatment of melanoma.

Emory University's research team is currently leading the way to improve the efficacy of CD28 to improve the effectiveness of cancer immunotherapy. The strategy is to take CD28 as a precursor molecular marker to screen the most appropriate cancer patients to enhance the efficacy of tumor immunotherapy. Flarebio provides superior recombinant proteins including recombinant CDH2 for your research.